Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Obesity | Research article

Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia

Authors: Jianzhen Zhang, Helen G. Healy, Sree Krishna Venuthurupalli, Ken-Soon Tan, Zaimin Wang, Anne Cameron, Wendy E. Hoy

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

High blood pressure is the most significant risk factor for the development and progression of chronic kidney disease (CKD). Lowering blood pressure is a goal to prevent CKD progression. This study of adults with CKD who have hypertension aimed to determine blood pressure control rates and the treatment patterns of hypertension and to explore factors associated with control of hypertension.

Methods

This cross-sectional study included all non-dialysis people with CKD stages 3A to 5 under nephrology care in three public renal clinics in Queensland, who joined the CKD.QLD registry from May 2011 to Dec 2015 and had a history of hypertension. Demographic information, other health conditions, laboratory markers and anti-hypertensive medications in use at consent were extracted from the registry.

Results

Among 1814 CKD people in these three sites in the registry who were age ≥ 18 years and had CKD stage 3A to 5, 1750 or 96% had a history of hypertension. Of these, the proportion with BP control to < 140/90 mmHg was 61.7% and to < 130/80 mmHg was 36.3%. With target BP < 140/90 mmHg or < 130/80 mmHg, participants aged ≥65 years were 1.23 (95% CI 1.06–1.42) or 1.12 (1.03–1.22) times more likely to have uncontrolled BP compared to those < 65 years old. Participants with severe albuminuria or proteinuria were 1.58 (1.32–1.87) or 1.28 (1.16–1.42, p < 0.001) more likely to have uncontrolled BP compared to those without significant albuminuria or proteinuria. Participants who had cardiovascular disease (CVD) were less likely to have uncontrolled BP compared to those without CVD (0.78, 0.69–0.89 or 0.86, 0.80–0.92). Factors associated with use of more classes of antihypertensive medicines among participants with uncontrolled BP (> 140/90 mmHg) were older age, diabetes, CVD, obesity and severe albuminuria/proteinuria (p < 0.05). Renin Angiotensin Aldosterone System inhibitors were the most frequently used medicines, regardless of the number of medicine classes an individual was prescribed.

Conclusions

Blood pressure control rates in these hypertensive people with CKD was still far from optimal. People with CKD and hypertension aged 65 or older or with severe albuminuria or proteinuria, a group at risk of progression of kidney disease, have higher rates of uncontrolled BP.
Literature
1.
go back to reference Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–60.CrossRef Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224–60.CrossRef
2.
go back to reference Barri Y. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep. 2008;10:39–45.CrossRef Barri Y. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep. 2008;10:39–45.CrossRef
3.
go back to reference Graeme Turner KW, Johnson D. Primary prevention of chronic kidney disease: blood pressure targets: chronic kidney disease guidelines. KHA-CARI guidelines: KHA; 2012. Graeme Turner KW, Johnson D. Primary prevention of chronic kidney disease: blood pressure targets: chronic kidney disease guidelines. KHA-CARI guidelines: KHA; 2012.
4.
go back to reference Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55(3):441–51.CrossRef Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55(3):441–51.CrossRef
5.
go back to reference Maura Ravera MR, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006;17(4):S98–S103.CrossRef Maura Ravera MR, Deferrari L, Vettoretti S, Deferrari G. Importance of blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006;17(4):S98–S103.CrossRef
6.
go back to reference Kidney Health Australia. Fast facts chronic Kideny disease in Australia. In: Australia KH, editor. Kidney fast factswww.kidney.org.au: Kidney Health Australia; 2017. Kidney Health Australia. Fast facts chronic Kideny disease in Australia. In: Australia KH, editor. Kidney fast factswww.​kidney.​org.​au: Kidney Health Australia; 2017.
8.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO). Blood pressure work group. KDIGO clinical practice guideline for the Management of Blood Pressure in chronic kidney disease. Kidney Int. 2012;Suppl(2):337–414. Kidney Disease: Improving Global Outcomes (KDIGO). Blood pressure work group. KDIGO clinical practice guideline for the Management of Blood Pressure in chronic kidney disease. Kidney Int. 2012;Suppl(2):337–414.
9.
go back to reference Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(10):1498–505.CrossRef Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(10):1498–505.CrossRef
10.
go back to reference World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.CrossRef World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.CrossRef
11.
go back to reference Roberts MA. Commentary on the KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Nephrology. 2014;19(1):53–5.CrossRef Roberts MA. Commentary on the KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Nephrology. 2014;19(1):53–5.CrossRef
12.
go back to reference Kidney Health Australia. State of the nation: chronic kidney disease in Australia. South Melbourne: Kidney Health Australia; 2014. Kidney Health Australia. State of the nation: chronic kidney disease in Australia. South Melbourne: Kidney Health Australia; 2014.
13.
go back to reference Zanchetti A, Dominiczak A, Coca A, Tsioufis C, Clement DL, Agabiti Rosei E, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRef Zanchetti A, Dominiczak A, Coca A, Tsioufis C, Clement DL, Agabiti Rosei E, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.CrossRef
14.
go back to reference Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease—Australian facts: risk factors. Cardiovascular, diabetes and chronic kidney disease series no 4 cat no CDK 4. Canberra: AIHW; 2015. Australian Institute of Health and Welfare. Cardiovascular disease, diabetes and chronic kidney disease—Australian facts: risk factors. Cardiovascular, diabetes and chronic kidney disease series no 4 cat no CDK 4. Canberra: AIHW; 2015.
15.
go back to reference Venuthurupalli SK, Hoy WE, Healy HG, Salisbury A, Fassett RG, on behalf of the CKD.QLD group. CKD.QLD: chronic kidney disease surveillance and research in Queensland, Australia. Nephrol Dial Transplant. 2012;27(suppl 3):iii139–i45.CrossRef Venuthurupalli SK, Hoy WE, Healy HG, Salisbury A, Fassett RG, on behalf of the CKD.QLD group. CKD.QLD: chronic kidney disease surveillance and research in Queensland, Australia. Nephrol Dial Transplant. 2012;27(suppl 3):iii139–i45.CrossRef
16.
go back to reference Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia. BMC Nephrol. 2017;18(1):189.CrossRef Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia. BMC Nephrol. 2017;18(1):189.CrossRef
17.
go back to reference Thomas G, Xie D, Chen H-Y, Anderson AH, Appel LJ, Bodana S, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease. Rep Chronic Renal Insufficien Cohort Study. 2016;67(2):387–96. Thomas G, Xie D, Chen H-Y, Anderson AH, Appel LJ, Bodana S, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease. Rep Chronic Renal Insufficien Cohort Study. 2016;67(2):387–96.
19.
go back to reference Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(4):272–7.CrossRef Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(4):272–7.CrossRef
20.
go back to reference Williamson T, Eliasziw M, Fick GH. Log-binomial models: exploring failed convergence. Emerg Themes Epidemiol. 2013;10:14.CrossRef Williamson T, Eliasziw M, Fick GH. Log-binomial models: exploring failed convergence. Emerg Themes Epidemiol. 2013;10:14.CrossRef
21.
go back to reference Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.CrossRef Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.CrossRef
22.
go back to reference Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart. 2014;100(4):317–23.CrossRef Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart. 2014;100(4):317–23.CrossRef
24.
go back to reference Mani A. Albuminuria in hypertensive patients: where the choice of antihypertensive medications matters. J Clin Hypertens. 2016;18(1):31–2.CrossRef Mani A. Albuminuria in hypertensive patients: where the choice of antihypertensive medications matters. J Clin Hypertens. 2016;18(1):31–2.CrossRef
25.
go back to reference Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.CrossRef Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.CrossRef
26.
go back to reference Anonymous. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.CrossRef Anonymous. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.CrossRef
27.
go back to reference Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.CrossRef Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20(8):1813–21.CrossRef
28.
go back to reference David W, Johnson GRDJ, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. 2012;197(4):224–5. David W, Johnson GRDJ, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. 2012;197(4):224–5.
29.
go back to reference Jafar TH, Stark PC, Schmid CH, Landa M, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244–52.CrossRef Jafar TH, Stark PC, Schmid CH, Landa M, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139(4):244–52.CrossRef
30.
go back to reference Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract. 2008;62(1):97–108.CrossRef Volpe M. Microalbuminuria screening in patients with hypertension: recommendations for clinical practice. Int J Clin Pract. 2008;62(1):97–108.CrossRef
31.
go back to reference Australian Government Department of Health and Aging. Towards a national primary health care strategy: a discussion paper from the Australian government. Canberra: Commonwealth of Australia; 2008. Australian Government Department of Health and Aging. Towards a national primary health care strategy: a discussion paper from the Australian government. Canberra: Commonwealth of Australia; 2008.
32.
go back to reference Handler J. The importance of accurate blood pressure measurement. Perm J. 2009;13(3):51–4.CrossRef Handler J. The importance of accurate blood pressure measurement. Perm J. 2009;13(3):51–4.CrossRef
33.
go back to reference Campbell NRC, Lackland DT, Niebylski ML, the World Hypertension L, International Society of Hypertension Executive C. High blood pressure: why prevention and control are urgent and important—a 2014 fact sheet from the world hypertension league and the International Society of Hypertension. J Clin Hypertens. 2014;16(8):551–3.CrossRef Campbell NRC, Lackland DT, Niebylski ML, the World Hypertension L, International Society of Hypertension Executive C. High blood pressure: why prevention and control are urgent and important—a 2014 fact sheet from the world hypertension league and the International Society of Hypertension. J Clin Hypertens. 2014;16(8):551–3.CrossRef
34.
go back to reference Campbell N, Ordunez P, Jaffe MG, Orias M, DiPette DJ, Patel P, et al. Implementing standardized performance indicators to improve hypertension control at both the population and healthcare organization levels. J Clin Hypertens. 2017;19(5):456–61.CrossRef Campbell N, Ordunez P, Jaffe MG, Orias M, DiPette DJ, Patel P, et al. Implementing standardized performance indicators to improve hypertension control at both the population and healthcare organization levels. J Clin Hypertens. 2017;19(5):456–61.CrossRef
35.
go back to reference National Heart Fundation of Australia. Guideline for the diagnosis and managment of hypertension in adults Melbourne National Heart Fundation of Australia; 2016. National Heart Fundation of Australia. Guideline for the diagnosis and managment of hypertension in adults Melbourne National Heart Fundation of Australia; 2016.
37.
go back to reference Garofalo C, Borrelli S, Provenzano M, De Stefano T, Vita C, Chiodini P, et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials. Nutrients. 2018;10(6):732.CrossRef Garofalo C, Borrelli S, Provenzano M, De Stefano T, Vita C, Chiodini P, et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials. Nutrients. 2018;10(6):732.CrossRef
38.
go back to reference INET-CKD. Internaitonal variation of hypertension control and treatment in CKD patients; 2016. INET-CKD. Internaitonal variation of hypertension control and treatment in CKD patients; 2016.
39.
go back to reference Dienemann T, Fujii N, Orlandi P, Nessel L, Furth SL, Hoy WE, et al. International network of chronic kidney disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. BMC Nephrol. 2016;17(1):121.CrossRef Dienemann T, Fujii N, Orlandi P, Nessel L, Furth SL, Hoy WE, et al. International network of chronic kidney disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts. BMC Nephrol. 2016;17(1):121.CrossRef
Metadata
Title
Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia
Authors
Jianzhen Zhang
Helen G. Healy
Sree Krishna Venuthurupalli
Ken-Soon Tan
Zaimin Wang
Anne Cameron
Wendy E. Hoy
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1532-6

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue